Amgen says its blood cancer drug gets European backing for extended indication
July 4, 2016Research and Development, Sales and Marketing Amgen, European Commission, Kyprolis, blood cancer, drug trial
Amgen (Nasdaq: AMGN) said the European Commission (EC) has approved a variation to the marketing authorization for its Kyprolis (carfilzomib) to include use …
Merck says its Erbitux in combination with Folfox improves outcomes in colorectal cancer
July 4, 2016Research and Development, Sales and Marketing Cancer, China, ESMO, Merck, colorectal cancer, drug trial, research, study
Merck said late-stage trials for its Erbitux (cetuximab) in combination with Folfox significantly improved progression free survival in metastatic colorectal …
Weekly Movers: Regulus, Nymox, Akers…
July 4, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shares, drug trial, markets, stocks
Shares in Regulus Therapeutics (Nasdaq: RGLS) dropped after the company said it has received verbal notification from the US Food …
AstraZeneca licenses skin-condition drug to Leo Pharma for $115 million upfront
July 1, 2016Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Deals, Licencing, Loe Pharna, Valeant, drug development
UK drug firm AstraZeneca (LSE: AZN) said it has licenced its drug for skin diseases to Leo Pharma for an …
US doctors received $6.5 billion from drug, device firms in 2015
July 1, 2016Medical Communications, Research and Development, Sales and Marketing US, affordable care act, pharma, regulation
Doctors and hospitals received nearly $6.5 billion in research and speaking fees as well as other goods or services from …
UK healthcare professionals received £340.3 million in benefits from pharma industry in 2015 discloses ABPI
July 1, 2016Business Services, Medical Communications, Sales and Marketing ABPI, Pharmacutical, corruption, disclosure, regulation
“We don’t want our neighbours to know what we earn,” said Mike Thompson, the chief executive of industry body Association …
AbbVie’s Imbruvica secures fourth breakthrough therapy designation from US FDA
July 1, 2016Medical Communications, Research and Development, Sales and Marketing AbbVie, US FDA, drug trial, imbruvica
US pharma firm AbbVie (NYSE: ABBV) said the US Food and Drug Administration has granted Imbruvica a fourth breakthrough therapy …
Shire says Phase II trial for rare eye condition in premature infants fails
July 1, 2016Medical Communications, Research and Development Shire, US FDA, drug trial, rare eye condition in infants
Shire plc (LSE: SHP) said its drug compound to treat a rare eye condition in infants failed mid-stage trials. The …
Bayer says its Stivarga improved overall survival in liver cancer in late-stage trials
June 30, 2016Research and Development, Sales and Marketing Bayer, Stivarga, drug trial, liver cancer
German pharma and crop sciences giant Bayer (ETR: BAYN) said late-stage trials for its drug to treat liver cancer showed a …
Galena’s breast cancer immunotherapy fails in late-stage trials; shares plunge
June 30, 2016Research and Development, Sales and Marketing Galena Biopharma, Stock, breast cancer, drug trial
Shares in Galena Biopharma (Nasdaq: GALE) dropped over 80% after the company said an independent Data Monitoring Committee recommended that …
Tesaro’s niraparib hits primary goal in late-stage trials for ovarian cancer trial; shares jump
June 30, 2016Research and Development, Sales and Marketing Tesaro, drug trial, niraparib, ovarian cancer
Shares in Tesaro (Nasdaq: TSRO) jumped to more than double after the company reported late-stage trials for its drug to …
Eli Lilly says FDA panel backs approval of Jardiance for cardiovascular indication
June 30, 2016Research and Development, Sales and Marketing Eli Lilly, cardiovascular, diabetes, jardiance
US drugmaker Eli Lilly (NYSE: LLY) said a US regulatory panel has backed its Jardiance (empagliflozin) for reducing cardiovascular death …
Shire says trial drug for ADHD shows positive results
June 30, 2016Research and Development, Sales and Marketing ADHD, Shire, US FDA, drug trial, regulation
UK drugmaker Shire plc (LSE: SHP) said its trial drug to treat Attention-Deficit/Hyperactivity Disorder (ADHD) showed positive topline results. Philip …
Regulus’ shares drop as FDA puts trials for hepatitis C drug on hold
June 29, 2016Research and Development, Sales and Marketing Regulus Therapeutics, US FDA, drug trial, hepatitis C virus, regulation
Shares in Regulus Therapeutics (Nasdaq: RGLS) plunged as much as 60% after the company said the US Food and Drug …
Mayne Pharma to buy a portfolio of Teva’s generic drugs for $652 million
June 29, 2016Research and Development, Sales and Marketing Allergan, Deals, Mayne Pharma, Teva, generics, merger and acquisition
Australia’s Mayne Pharma Group Ltd (ASX: MYX) said it will acquire US generic products from Israel-based drugmaker Teva Pharmaceuticals (NYSE: …
Pfizer to invest about $350 million in China biotech facility, first in Asia
June 29, 2016Research and Development, Sales and Marketing Biotech Plant, China, Pfizer, research
US pharma giant Pfizer (NYSE: PFE) said it will invest about $350 million for a global biotechnology center in the …
Gilead says US FDA approves Epclusa to treat hepatitis C
June 29, 2016Research and Development, Sales and Marketing Epclusa, Gilead, HCV, US FDA, drug approval, regulation
US drug firm Gilead Sciences (Nasdaq: GILD) said the US Food and Drug Administration has approved its Epclusa (sofosbuvir/velpatasvir), in …
AstraZeneca’s new antibiotic Zavicefta gets European approval for serious bacterial infections
June 29, 2016Research and Development, Sales and Marketing AstraZeneca, European Commission, Zavicefta, bacterial infections, regulation
UK drug firm AstraZeneca (LSE: AZN) said the European Commission has granted marketing authorisation for its Zavicefta (ceftazidime-avibactam), a new combination …
Roche says EMA accepts its marketing applications for Ocrevus to treat multiple sclerosis
June 28, 2016Manufacturing and Production, Research and Development, Sales and Marketing EMA, Ocrevus, Roche, US FDA, drug development, drug trial, multiple sclerosis, priority review, regulation
Cancer drugmaker Roche (SIX: ROG) said the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for its …
Novo Nordisk says its insulin pump secures EMA marketing authorisation
June 28, 2016Manufacturing and Production, Research and Development, Sales and Marketing EMA, Novo Nordisk, insulin pump, marketing, product launch
Diabetes drugmaker Novo Nordisk (NYSE: NYO) said it has secured European Medicines Agency (EMA) marketing approval for its insulin pump. …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
